Results 151 to 160 of about 12,272 (191)

Modulation of atherogenesis biomarkers by PCSK9 inhibitors in Lp(a)-stimulated human coronary artery endothelial cells. [PDF]

BMC Cardiovasc Disord
Zulkapli R, Muid SA, Wang SM, Putera Mohd Yusof MY, Nawawi H.   +4 more
europepmc   +1 more source

Current and future role of PCSK9 inhibitors in ASCVD prevention. [PDF]

Future Cardiol
Greco A, Capodanno D.
europepmc   +1 more source

Surface-modified extracellular vesicles take their chance in the big PCSK9 inhibitors' race. [PDF]

Mol Ther
Ben-Aicha S, Emanueli C.
europepmc   +1 more source

Pleiotropic Effects of PCSK9 Inhibitors on Cardio-Cerebrovascular Diseases. [PDF]

Biomedicines
Li Z, Zhu L, Xu Y, Zhang Y, Liu Y, Sun H, Li S, Wang M, Jiang T, Zhou J, Deng Q.   +10 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

PCSK9 inhibitors for treating hypercholesterolemia

Expert Opinion on Pharmacotherapy, 2020
Introduction: Scientific evidence on subjects treated with statin or other lipid-lowering treatments has established that treatments aiming to lower low-density lipoprotein cholesterol (LDL-C) can reduce atherosclerosis. PCSK9 inhibitors (PCSK9-i), thanks to their efficacy in reducing LDL-C constitute a further step in the treatment of dyslipidemia and
Livia Pisciotta, Anna Laura Cremonini, Italo Porto   +2 more
exaly   +3 more sources

Oral PCSK9 Inhibitors

Current Atherosclerosis Reports
In this review, we will discuss the data from early clinical studies of MK-0616 and summarize clinical trials of other oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.The success of PCSK9 inhibition with monoclonal antibody injections has fueled the development of additional therapies targeting PCSK9, including oral formulations ...
Christie Ballantyne, Anandita Agarwala, Ballantyne Christie M   +2 more
exaly   +4 more sources

PCSK9 inhibitors

Current Opinion in Lipidology, 2013
To summarize the therapeutic strategies to inhibit PCSK9 and to describe the main results obtained in phase I and II trials with monoclonal antibodies targeting PCSK9.Among the various approaches for PCSK9 inhibition, human data are only available for inhibition of PCSK9 binding to LDL receptor by monoclonal antibodies.
openaire   +2 more sources

PCSK9 inhibitors and cardiovascular outcomes

Expert Opinion on Biological Therapy, 2019
Introduction: Dyslipidemia, particularly elevated low-density lipoprotein cholesterol (LDL-C), is a key risk factor for atherosclerotic cardiovascular disease (ASCVD), and lipid-lowering drugs are beneficial for the primary and secondary prevention of cardiovascular (CV) disease.
Daniel, Steffens, Peter, Bramlage, Céline, Scheeff, Mario, Kasner, Adel, Hassanein, Julian, Friebel, Ursula, Rauch-Kröhnert   +6 more
openaire   +2 more sources